Ocular Hypertension Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 50+ Leading Players Wheeling the Therapeutics Landscape

(Albany, US) October 13, 2026- DelveInsight’s, “Ocular Hypertension Pipeline Insight, 2026” report provides comprehensive insights about 50+ companies and 75+ pipeline drugs in Ocular Hypertension pipeline landscape. It covers the Ocular Hypertension pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Ocular Hypertension pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ https://www.delveinsight.com/sample-request/ocular-hypertension-pipeline-insight

Key Takeaways from the Ocular Hypertension Pipeline Report

• On October 12, 2026 – SpyGlass Pharma Inc presented 12-month interim findings from a Phase I/II clinical trial of SpyGlass Pharma’s investigational bimatoprost-eluting intraocular lens (BIM-IOL) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting. The device demonstrated sustained intraocular pressure (IOP) reductions of approximately 33–42% in patients with mild-to-moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery. At 12 months, 96–98% of patients in the BIM-IOL groups remained free of additional IOP-lowering medications, highlighting the potential of sustained drug delivery to reduce dependence on daily eye drops.
• On October 9, 2026 – Glaukos Corporation announced positive topline results from the Phase IV GLK-101-04 clinical trial evaluating iDose TR (travoprost intracameral implant) in combination with cataract surgery in patients with open-angle glaucoma or ocular hypertension. At three months, patients receiving iDose TR alongside cataract surgery experienced a mean intraocular pressure (IOP) reduction of 11.1 mmHg, compared with 7.4 mmHg among patients undergoing cataract surgery alone. The findings highlight the potential of sustained-release therapies to improve IOP management and reduce dependence on daily eye drops.
• DelveInsight’s Ocular Hypertension pipeline report depicts a robust space with 50+ active players working to develop 75+ pipeline therapies for Ocular Hypertension treatment.
• The leading Ocular Hypertension Companies such as Santen Pharmaceutical, Nicox Ophthalmics, Inc., Allysta Pharmaceuticals, Qlaris Bio, Inc., Ripple Therapeutics, Laboratoires Thea, Ocular Therapeutix, Inc., Otsuka Beijing Research Institute, Alcon Research, AbbVie, Glaukos Corporation, MediPrint Ophthalmics, Ocuphire Pharma and others.
• Promising Ocular Hypertension Pipeline Therapies such as NCX 470, Nyxol, Sepetaprost(DE-126/ONO-9054/STN1012600 ), LL-BMT1, PDP-716, V-GL1, NCX 470, Kinezodianone R hydrochloride, G2-TR intraocular implant containing travoprost, H-1337, AGN-193408 SR, Latanoprost ophthalmic solution, OTX-TIC, PER-001, and others.

Learn how leading Ocular Hypertension Companies are positioning themselves for success in the evolving pharmaceutical market @ Ocular Hypertension Clinical Trials Assessment

Ocular Hypertension Overview

Ocular hypertension is a condition characterized by elevated pressure inside the eye, which occurs when the aqueous humor, a fluid responsible for nourishing the eye and maintaining its shape, doesn’t drain properly. Although individuals with ocular hypertension often experience no noticeable symptoms or changes to their vision, the condition can increase the risk of developing glaucoma, a more serious eye disorder that causes structural damage and potential vision loss. While ocular hypertension does not always progress to glaucoma, regular monitoring by an eye care professional is essential to detect any early signs of damage and manage the condition effectively. Lifestyle factors, such as diet and stress levels, may also play a role in managing eye pressure, though medication or other treatments may be necessary for some individuals. Early intervention can help prevent long-term damage and preserve vision.

Ocular Hypertension Emerging Drugs Profile

• Sepetaprost: Santen Pharmaceutical

Sepetaprost (STN1012600) is a dual agonist of the FP and EP3 receptors, using as its active ingredient sepetaprost, a compound originally developed and manufactured by Ono Pharmaceutical Co., Ltd. STN1012600 is a prostaglandin derivative for the treatment of glaucoma and ocular hypertension that contains 0.002% sepetaprost and has a novel mechanism of action for lowering intraocular pressure. It works by selectively binding to both the FP and EP3 receptors in the eye, promoting increased aqueous humor outflow through both the uveoscleral and trabecular pathways. This dual action helps to lower intraocular pressure more effectively. By targeting these specific receptors, STN1012600 may offer improved efficacy with fewer side effects compared to traditional treatments. Currently, the drug is in Preregistration stage of its development for the treatment of Ocular Hypertension.

• NCX 470: Nicox Ophthalmics, Inc.

NCX 470 is a novel nitric oxide (NO)-donating bimatoprost eye drop that leverages the potent intraocular pressure (IOP)-lowering effects of NO and prostaglandin analogs (PGAs). NCX 470 incorporates Nicox’s proprietary NO-donating research platform and bimatoprost in a single molecule. NCX 470 is designed to release bimatoprost and NO into the eye to lower IOP by two different pathways in patients with open-angle glaucoma or ocular hypertension. NO is a well-known small, naturally occurring signaling molecule that plays a key role in the regulation of IOP through activation of soluble guanylate cyclase (sGC). NO brings additional IOP-lowering efficacy by enhancing aqueous humor drainage from the eye via a different mechanism of action to that of PGAs. Currently, the drug is in Phase III stage of its development for the treatment of Ocular Hypertension.

• QLS-111: Qlaris Bio, Inc.

QLS-111 is a novel formulation developed by Qlaris Bio that utilizes an ATP-sensitive potassium (KATP) channel modulator platform to effectively lower intraocular pressure (IOP). Its mechanism of action involves relaxing the vascular and vascular-like tissues located distal to the trabecular meshwork, which leads to a reduction in distal outflow resistance. By enhancing the outflow of aqueous humor, QLS-111 simultaneously lowers episcleral venous pressure (EVP), a critical factor that contributes significantly to IOP. This dual action not only helps to alleviate the pressure within the eye but also addresses an often-overlooked component of IOP regulation, potentially offering a more comprehensive approach to managing conditions such as glaucoma and ocular hypertension. Currently, the drug is in Phase II stage of its development for the treatment of Ocular Hypertension.

• H-1337: Allysta Pharmaceuticals

H-1337 is an advanced multi-kinase inhibitor under development for the treatment of glaucoma and ocular hypertension, designed to lower intraocular pressure (IOP) through a novel mechanism of action. This compound primarily inhibits leucine-rich repeat kinase 2 (LRRK2), a serine/threonine kinase that plays a vital role in regulating the cytoskeletal dynamics of trabecular meshwork cells. By inhibiting LRRK2, H-1337 promotes the depolymerization of microtubules within these cells, leading to structural changes that enhance aqueous humor drainage through the trabecular meshwork and Schlemm’s canal. Additionally, H-1337 also exhibits secondary activity as a Rho-associated protein kinase (ROCK) inhibitor, further contributing to its efficacy in reducing IOP. This dual-action approach not only addresses the primary challenge of elevated IOP in glaucoma patients but also positions H-1337 as a promising candidate for improving overall ocular health. Currently, the drug is in Phase II stage of its development for the treatment of Ocular Hypertension.

• RTC-1119: Ripple Therapeutics

RTC-1119 is an innovative intracameral implant developed by Ripple Therapeutics for the treatment of primary open-angle glaucoma. This formulation utilizes a unique prodrug of latanoprost acid, designed to provide sustained release of the active drug through a surface erosion mechanism. The implant is engineered to dissolve gradually, allowing for controlled and predictable drug delivery over an extended period, typically exceeding six months. By enhancing the outflow of aqueous humor and reducing intraocular pressure (IOP), RTC-1119 aims to improve patient compliance and therapeutic outcomes in managing glaucoma. The absence of polymers in its composition further minimizes potential inflammatory responses, making RTC-1119 a promising candidate in the evolving landscape of glaucoma therapies. Currently, the drug is in Preclinical stage of its development for the treatment of Ocular Hypertension.

The Ocular Hypertension Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Ocular Hypertension with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ocular Hypertension Treatment.
• Ocular Hypertension Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Ocular Hypertension Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ocular Hypertension market.

From early-stage research to late-phase Ocular Hypertension Clinical Trials, our analysis covers key companies, innovative treatment approaches @ Ocular Hypertension Treatment Drugs

Ocular Hypertension Companies

Santen Pharmaceutical, Nicox Ophthalmics, Inc., Allysta Pharmaceuticals, Qlaris Bio, Inc., Ripple Therapeutics, Laboratoires Thea, Ocular Therapeutix, Inc., Otsuka Beijing Research Institute, Alcon Research, AbbVie, Glaukos Corporation, MediPrint Ophthalmics, Ocuphire Pharma and others.

Ocular Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Ocular Hypertension Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Download our report for a deep dive into the next generation of therapeutics! @ Ocular Hypertension Market Drivers and Barriers, and Future Perspectives

Scope of the Ocular Hypertension Pipeline Report

• Coverage- Global
• Ocular Hypertension Companies- Santen Pharmaceutical, Nicox Ophthalmics, Inc., Allysta Pharmaceuticals, Qlaris Bio, Inc., Ripple Therapeutics, Laboratoires Thea, Ocular Therapeutix, Inc., Otsuka Beijing Research Institute, Alcon Research, AbbVie, Glaukos Corporation, MediPrint Ophthalmics, Ocuphire Pharma and others.
• Ocular Hypertension Pipeline Therapies- NCX 470, Nyxol, Sepetaprost(DE-126/ONO-9054/STN1012600 ), LL-BMT1, PDP-716, V-GL1, NCX 470, Kinezodianone R hydrochloride, G2-TR intraocular implant containing travoprost, H-1337, AGN-193408 SR, Latanoprost ophthalmic solution, OTX-TIC, PER-001, and others.
• Ocular Hypertension Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Ocular Hypertension Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find answers in our latest Ocular Hypertension Pipeline Insights report, featuring in-depth coverage of Clinical Trials @ Ocular Hypertension Emerging Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Ocular Hypertension: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Ocular Hypertension– DelveInsight’s Analytical Perspective
7. Late Stage Products (Preregistration)
8. Sepetaprost: Santen Pharmaceutical
9. Mid Stage Products (Phase II)
10. QLS-101: Qlaris Bio
11. Early Stage Products (Phase I/II)
12. Drug name: Company name
13. Preclinical and Discovery Stage Products
14. RTC-1119: Ripple Therapeutics
15. Inactive Products
16. Ocular Hypertension Key Companies
17. Ocular Hypertension Key Products
18. Ocular Hypertension- Unmet Needs
19. Ocular Hypertension- Market Drivers and Barriers
20. Ocular Hypertension- Future Perspectives and Conclusion
21. Ocular Hypertension Analyst Views
22. Ocular Hypertension Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/ocular-hypertension-pipeline-insight